Deals: Page 3

  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers pours $100M into RNA drugs for cardiovascular diseases

    Tuesday’s deal signals the pharmaceutical giant's confidence in Avidity Biosciences and its so-called antibody oligonucleotide conjugates.

    By • Nov. 28, 2023
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck to buy private biotech Caraway in neuroscience deal

    In a deal worth up to $610 million, Merck will gain a pipeline of neuroscience and rare disease programs from a startup it previously backed.

    By • Nov. 21, 2023
  • Explore the Trendline➔
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A. 

    By BioPharma Dive staff
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Homology enters reverse merger with Q32 Bio

    The deal, which will result in a combined company operating under Q32's name, comes months after Homology laid off much of its staff.

    By • Nov. 16, 2023
  • A sign showing Gilead's logo
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead expands Arcellx cancer cell therapy deal

    The deal gives Gilead an estimated 13% ownership in Arcellx and extends the company’s cash runway into 2027.

    By • Nov. 15, 2023
  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip

    Novartis licenses Legend cell therapy for lung cancer

    With the deal, the Swiss pharma is exploring a tumor target, DLL3, that’s thwarted past drugmaker efforts to attack it.

    By • Nov. 13, 2023
  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip
    Obesity drugs

    AstraZeneca stays in GLP-1 drug race with new deal

    AstraZeneca is paying $185 million upfront to gain access to an experimental GLP-1 drug from China-based biotech Eccogene.

    By • Nov. 9, 2023
  • Scientists at Orum Therapeutics observing the physical appearance of an experiment.
    Image attribution tooltip
    Permission granted by Orum Therapeutics
    Image attribution tooltip

    Bristol Myers pays $100M for a different kind of ADC

    A deal with Orum Therapeutics gives the large pharma access to a blood and bone marrow cancer drug that's ready to enter clinical testing.

    By • Nov. 6, 2023
  • A horizontal headshot of Roivant Sciences chief executive officer Matt Gline.
    Image attribution tooltip
    Permission granted by Roivant Sciences
    Image attribution tooltip

    Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

    The sale of Telavant and its TL1A drug was born out of a J.P. Morgan conference meeting, Roivant head Matt Gline said, and reflected the biotech’s flexible strategy.

    By Michael Gibney • Oct. 31, 2023
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi invests in MeiraGTx and its gene-regulating technology

    In addition to Sanofi’s investment, the biotech signaled it’s weighing deals with “multiple” other companies that have expressed interest in its work.

    By • Oct. 30, 2023
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi to divest consumer unit, joining pharma industry shift

    The restructuring came as the French company forecast an earnings drop in 2024, prompting a stock selloff that erased about $20 billion in market value.

    By • Oct. 27, 2023
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    Amgen to lay off 350 Horizon staffers weeks after closing $28B deal

    The latest round of cuts brings the company’s total announced workforce reductions this year to more than 1,000.

    By Kristin Jensen • Oct. 25, 2023
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip
    Emerging biotech

    OrbiMed raises $4.3B in new funds for startup investing

    The money will be spread across three investment funds and comes at a time when investment into biotech remains shakier than in years past.

    By • Oct. 24, 2023
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche to gain gut disease drug in $7.1B deal for Roivant subsidiary

    The Swiss pharma has agreed to buy Televant, a company set up by Roivant and Pfizer to develop a promising inflammatory bowel disease treatment.

    By • Oct. 23, 2023
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck cancer drug deal caps pharma investment influx into ‘ADC’ field

    With the alliance, Merck joins Pfizer, AstraZeneca and Gilead in staking major bets on the potential for antibody-drug conjugates to reshape cancer treatment.

    By • Oct. 20, 2023
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche is stuck on molecular glue

    One month after Roche’s Genentech inked a similar deal, the Swiss pharma is now paying $50 million to work with Monte Rosa on molecular glue medicines for cancer and neurological diseases.

    By • Oct. 17, 2023
  • A flag with the Novo Nordisk logo.
    Image attribution tooltip
    Novo Nordisk
    Image attribution tooltip

    Novo adds to deal spree with blood pressure drug buy

    Worth up to $1.3 billion, the deal with Singapore-based KBP Biosciences builds the Ozempic maker’s armory of metabolic disease drugs.

    By • Oct. 16, 2023
  • The front of the department of health and human services building with a sign in front of the exterior building
    Image attribution tooltip
    Mark Wilson via Getty Images
    Image attribution tooltip

    ‘Project NextGen’ picks new mRNA, intranasal COVID vaccines for funding

    The awards, to biotechs Gritstone, Codagenix and CastleVax, are part of the program’s plan to develop vaccines with broader or longer-lasting benefits.

    By • Oct. 13, 2023
  • European Union flags are pictured outside the European Commission building on October 24, 2014 in Brussels, Belgium.
    Image attribution tooltip
    Flickr: Eoghan OLionnain
    Image attribution tooltip

    European Commission orders Illumina to divest Grail

    The order includes an undisclosed timeline and potential additional fines. Illumina, which has been anticipating the decision, maintains the commission does not have jurisdiction over the completed merger.

    By Susan Kelly • Oct. 12, 2023
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip

    After summer slump, biotech M&A has a good week

    There have been few bigger-ticket acquisitions recently. But a string of deals announced in early October, including the purchase of Orchard Therapeutics, may affirm the forecasts of analysts who expect M&A to tick up.

    By • Oct. 10, 2023
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers to buy KRAS cancer drug developer Mirati for $4.8B

    Mirati investors could also receive another $1 billion should an experimental cancer drug the biotech is developing make it to U.S. regulators’ desks.

    By • Oct. 8, 2023
  • Large letters spelling Amgen are seen next to a stone wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Amgen completes $28B Horizon buyout that was challenged by FTC

    Regulators’ holdup of the deal had stoked investor fears of greater scrutiny on M&A. In the end, Amgen agreed to requirements meant to guard against product “bundling.”

    By • Oct. 6, 2023
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie acquires Parkinson’s drug in latest biotech buyout

    The company exercised an option to buy Mitokinin, a private, Pfizer-backed drugmaker built on work by scientific co-founders Nicholas Hertz and Kevan Shokat.

    By • Oct. 5, 2023
  • Intellia Therapeutics
    Image attribution tooltip
    Permission granted by Intellia Therapeutics
    Image attribution tooltip

    Regeneron, Intellia target neurological diseases in expanded gene editing deal

    The longtime partners believe that, by combining their technologies, they can create “in vivo” genetic medicines for nervous system and muscular disorders.

    By • Oct. 3, 2023
  • Prostate cancer cells, 3D illustration. Prostate cancer awareness image
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Lilly to enter radiopharmaceutical drug field with $1.4B Point buyout

    Point Biopharma is one of the most advanced in a group of emerging biotechs working on radioligand therapies for cancer.

    By • Oct. 3, 2023
  • A corporate building is seen with a sign for the company Viatris
    Image attribution tooltip
    Courtesy of Viatris
    Image attribution tooltip

    Viatris sells off consumer, women’s health drugs in asset sales

    The divestments will bring in more than $3 billion as the company works to reduce its debt and plan for future business development.

    By • Oct. 2, 2023